Literature DB >> 1748155

Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs.

P C Wong1, S D Hart, J V Duncia, P B Timmermans.   

Abstract

DuP 753 (or EXP3174) and PD123177 are nonpeptide angiotensin (AII)-specific ligands, which show high affinities for two AII receptor subtypes, i.e. AT1 and AT2 sites, respectively. In furosemide-treated conscious dogs with high renin, DuP 753 and EXP3714, but not PD123177, were as effective as captopril in lowering blood pressure. Both DuP 753 and EXP3174 exhibited selective vascular antagonism of AII. In conscious dogs with normal renin, DuP 753, but not captopril or EXP3174, caused a dose-dependent but transient decrease in blood pressure. In anesthetized dogs, DuP 753 and captopril caused similar renal vasodilatation and natriuresis. The renal hemodynamic effects of DuP 753 and captopril were more pronounced in dogs with sodium depletion. These results suggest that the AT1 receptor mediates the pressor and renal effects of AII in dogs. The acute transient hypotensive effect of DuP 753 in normal-renin conscious dogs is probably unrelated to AII antagonism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748155     DOI: 10.1016/0014-2999(91)90274-t

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.

Authors:  D P Brooks; T A Fredrickson; J Weinstock; R R Ruffolo; R M Edwards; M Gellai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

2.  Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.

Authors:  B I Levy; J Benessiano; D Henrion; L Caputo; C Heymes; M Duriez; P Poitevin; J L Samuel
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

3.  Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Authors:  V Richard; B Ghaleh; A Berdeaux; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

4.  Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog.

Authors:  K L Clark; M J Robertson; G M Drew
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats.

Authors:  R E Widdop; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

6.  Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep.

Authors:  K M Stevenson; K J Gibson; E R Lumbers
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.

Authors:  P Bélichard; B Loillier; J L Paquet; J M Luccarini; D Pruneau
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 8.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

9.  Reversal of angiotensin-(1-12)-caused positive modulation on left ventricular contractile performance in heart failure: Assessment by pressure-volume analysis.

Authors:  Tiankai Li; Zhi Zhang; Xiaowei Zhang; Zhe Chen; Heng-Jie Cheng; Sarfaraz Ahmad; Carlos M Ferrario; Che Ping Cheng
Journal:  Int J Cardiol       Date:  2019-09-06       Impact factor: 4.164

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.